<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308374">
  <stage>Registered</stage>
  <submitdate>13/08/2009</submitdate>
  <approvaldate>2/03/2010</approvaldate>
  <actrnumber>ACTRN12610000185066</actrnumber>
  <trial_identification>
    <studytitle>Does exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in critically ill patients with pre-existing type-2 diabetes?</studytitle>
    <scientifictitle>The effect of exogenous glucagon-like peptide-1 (GLP-1) compared to placebo on glycaemia in critically ill patients with pre-existing type-2 diabetes during small intestinal feeding</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NA</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Blood Glucose</healthcondition>
    <healthcondition>Type-2 Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravenous Glucagon-like peptide-1 (reconstituted in 4%albumin) at 1.2pmol/kg/min will be administered for 270 min at 1ml/min. The infusion will commence 30 minutes prior to the commencement of intestinal nutrient infusion. Seperated by 24 hours the cross-over treatment is placebo (intravenous 4% Albumin at 1ml/min for 270 min), again commenced 30 minutes prior to intestinal nutrient infusion</interventions>
    <comparator>Cross-over study Cross-over treatment is 4% albumin infusion (which has no effect on blood glucose) infused at 1ml/min between t=0-270minutes</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Blood glucose during small intestinal feeding (as measured as Area under the curve)</outcome>
      <timepoint>4 hours (30-270 min)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood glucose (time above 10 mmol/l)</outcome>
      <timepoint>actual time.  Blood glucose will be monitored every 15 minutes throughout the study period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Peak blood glucose</outcome>
      <timepoint>actual time between t=30-270 min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Regulatory and counter-regulatory hormone release. Measured using plasma Insulin and glucagon concentrations</outcome>
      <timepoint>Every 30 minutes for the first 150 minutes and thereafter every 60 minutes until 270 min</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria
Critically ill patients with pre-existing type- 2 diabetes (not requiring insulin prior to hospital) and who require artificial ventilation
Likely to be ventilated for &gt;48hrs
Suitable to receive enteral nutrition via naso-jejunal feeding tube</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Age &lt;18 Age&gt;85 Pregnancy Small bowel obstruction History of insulin-requiring diabetes Previous surgery on the oesophagus, stomoach or duodenum Any gastrointestinal surgery on this admission</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients admitted to the Intensive Care Unit (ICU) of the Royal Adelaide Hospital will be screened. Next of kin will be approached for informed consent. Synthetic GLP-1-(7-36) amide is reconstituted by the Royal Adelaide Hospital department of pharmacy, as a solution in 4% albumin. Randomisation is performed by the department of pharmacy, so that on each study day the investigators receive the study drug in a glass bottle covered by black plastic</concealment>
    <sequence>computer sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>30/06/2009</anticipatedstartdate>
    <actualstartdate>1/07/2009</actualstartdate>
    <anticipatedenddate>30/06/2010</anticipatedenddate>
    <actualenddate>5/05/2010</actualenddate>
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Adam Deane</primarysponsorname>
    <primarysponsoraddress>Intensive Care Unit, Level 4,  Royal Adelaide Hospital North Terrace Adelaide SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to establish if glucagon-like peptide-1 (a hormone released from the gastrointestinal) has an effect on blood sugar levels in diabetic patients who are critically ill</summary>
    <trialwebsite />
    <publication>The results from this study were published in an international medical journal:

Crit Care. 2011;15(1):R35. 

Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.
Deane AM, Summers MJ, Zaknic AV, Chapman MJ, Fraser RJ, Di Bartolomeo AE, Wishart JM, Horowitz M.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committee</ethicname>
      <ethicaddress>Level 3 Hanson Insititute North Terrace Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>7/11/2008</ethicapprovaldate>
      <hrec>061229d</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Adam Deane</name>
      <address>Intensive Care Unit
Level 4
Royal Adelaide Hospital
North Terrace
Adelaide
SA 5000</address>
      <phone>+61 8 8222 4000</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Adam Deane</name>
      <address>Intensive Care Unit
Level 4
Royal Adelaide Hospital
North Terrace
Adelaide
SA 5000</address>
      <phone>+61 8 8222 4000</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Adam Deane</name>
      <address>Intensive Care Unit
Level 4
Royal Adelaide Hospital
North Terrace
Adelaide
SA 5000</address>
      <phone>+61 8 8222 4000</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Adam Deane </name>
      <address>Royal Adelaide Hospital
North Terrace
Adelaide, SA
5000</address>
      <phone>+61 8 8222 4000</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>